Hypogammaglobulinemia and Anti-CD20 Therapy-Induced Acute Thrombocytopenia: Perhaps More than a Coincidence?
Open Access
- 21 June 2024
- journal article
- case report
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 47 (9) , 434-438
Abstract
Introduction: The development of secondary hypogammaglobulinemia (sHGG) because of tumor treatment and/or the primary underlying hematologic disorder holds substantial clinical significance. B-cell-derived malignancies and anti-CD20 monoclonal antibodies (mAbs) represent important risk factors for the development of sHGG. In addition, the occurrence of acute thrombocytopenia (AT) induced by anti-CD20 therapy is a known, albeit rare, phenomenon. Case Presentation: A 54-year-old patient experiencing the first relapse of classical follicular lymphoma has commenced salvage therapy following the R-DHAP protocol. After rituximab infusion, platelet count dropped from 116 × 109/L to 13 × 109/L within 24 h. Reduced immunoglobulin G levels indicated moderate HGG; thus, we immediately administered intravenous immunoglobulins (IVIg). Within 5 days after initiation of IVIg, platelet count increased and stabilized at >50 × 109/L. Conclusions: It seems possible that anti-CD20 mAbs act like or activate similar mechanisms as autoantibodies in immune thrombocytopenia (ITP). Assuming that anti-CD20 therapy-induced AT is an ITP-like condition, HGG could be considered a potential risk factor. Thus, appropriate treatment of HGG with IVIg prior to anti-CD20 mAb therapy could potentially alleviate anti-CD20 therapy-induced AT.Keywords
This publication has 15 references indexed in Scilit:
- Frequency and outcomes of obinutuzumab‐induced thrombocytopeniaBritish Journal of Haematology, 2023
- Clinical and immunological characterisation of patients with common variable immunodeficiency related immune thrombocytopeniaClinical and Experimental Medicine, 2023
- Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute ThrombocytopeniaHemaSphere, 2022
- Pathogenesis of immune thrombocytopenia in common variable immunodeficiencyAutoimmunity Reviews, 2020
- Rituximab-Induced Acute Thrombocytopenia in a Patient with Relapsed Follicular LymphomaBlood, 2018
- Obinutuzumab for the First-Line Treatment of Follicular LymphomaNew England Journal of Medicine, 2017
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactionsBlood, 2015
- Rituximab‐induced thrombocytopenia: a cohort studyEuropean Journal of Haematology, 2012
- Morbidity and mortality in common variable immune deficiency over 4 decadesBlood, 2012
- Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopeniaBlood, 2011